{"id":"allergovac-depot","safety":{"commonSideEffects":["Injection site reactions","Local swelling","Mild allergic reactions"],"contraindications":["Severe uncontrolled asthma","Active autoimmune disease"]},"_chembl":null,"modality":"Biologic","_dailymed":null,"mechanism":{"explanation":"Allergovac depot works through allergen-specific immunotherapy, exposing patients to controlled amounts of allergens to induce immune tolerance. The depot formulation allows for sustained release of allergen extracts, potentially reducing injection frequency while maintaining therapeutic efficacy.","oneSentence":"Allergen immunotherapy that gradually desensitizes the immune system through repeated exposure to specific allergens in a depot formulation."},"_scrapedAt":"2026-03-28T02:21:36.922Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123517,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"Alutard SQ","brand":"Alutard SQ","company":"ALK-Abelló","rationale":"Allergen immunotherapy depot formulation for allergic conditions"},{"name":"Pollinex Quattro","brand":"Pollinex Quattro","company":"Allergy Therapeutics","rationale":"Short-course allergen immunotherapy for seasonal allergies"},{"name":"Depigoid","brand":"Depigoid","company":"Leti Pharma","rationale":"Depot allergen immunotherapy for respiratory allergies"}],"description":"Allergovac depot is an allergen immunotherapy product developed by Roxall Medicina España S.A. for the treatment of allergic conditions. It is designed as a depot formulation to provide sustained allergen exposure for desensitization therapy, currently in Phase 2 clinical development.","indications":{"approved":[{"status":"investigational","condition":"Allergic rhinitis","patientPopulation":"Adults and adolescents with confirmed allergen sensitivity"},{"status":"investigational","condition":"Allergic asthma","patientPopulation":"Patients with allergen-induced asthma"}]},"trialDetails":[{"nctId":"NCT03821077","phase":"","title":"Study to Evaluate the Efficacy and Safety of \"Allergovac Poliplus\" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma","status":"COMPLETED","sponsor":"Roxall Medicina España S.A","startDate":"2018-08-30","conditions":"Rhinitis, Allergic, Rhinoconjunctivitis","enrollment":122},{"nctId":"NCT01567306","phase":"PHASE2","title":"Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense","status":"COMPLETED","sponsor":"Roxall Medicina España S.A","startDate":"2011-10","conditions":"Allergic Rhinoconjunctivitis","enrollment":151},{"nctId":"NCT02849210","phase":"PHASE1","title":"A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea","status":"COMPLETED","sponsor":"Roxall Medicina España S.A","startDate":"2015-09","conditions":"Rhinoconjunctivitis","enrollment":47},{"nctId":"NCT02881879","phase":"PHASE1","title":"Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House Dust Mites","status":"COMPLETED","sponsor":"Roxall Medicina España S.A","startDate":"2016-07","conditions":"Allergic Rhinoconjunctivitis","enrollment":43},{"nctId":"NCT02477917","phase":"PHASE1","title":"A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica","status":"COMPLETED","sponsor":"Roxall Medicina España S.A","startDate":"2015-05","conditions":"Rhinoconjunctivitis","enrollment":51},{"nctId":"NCT01564017","phase":"PHASE2","title":"Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract","status":"COMPLETED","sponsor":"Roxall Medicina España S.A","startDate":"2012-05","conditions":"Allergic Rhinoconjunctivitis","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Allergovac"],"phase":"phase_2","status":"active","brandName":"Allergovac depot","genericName":"Allergovac depot","companyName":"Roxall Medicina España S.A","companyId":"roxall-medicina-espa-a-s-a","firstApprovalDate":"","aiSummary":"Allergovac depot is a subcutaneous immunotherapy used to treat conditions such as allergic rhinoconjunctivitis and rhinitis. It is a gonadotropin-releasing hormone receptor agonist, classified as an agonist drug modality.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}